糖尿病患者的致命性真菌感染：两性霉素B脂质复合物的治疗

下载PDF

导出

作者 Bade.,LM

出处《世界医学杂志》 1998年第11期37-40,共4页 International Journal of Medicine

关键词糖尿病真菌致病性两性霉素B 脂质体

参考文献20

1Perschel WT.Langefeld TW. Federlin K.Susceptibility to inlections in diabetes-effects on metabolism.Immun Infekt 1995,23:196-200.
2Schubert S,Heesemann J.Infections in diabeles mellitus.Immun Infekt 1995,23:200-4.
3Vazquez JA.Sobel JD.Eungal infections in diabetes.Infect Dis Clin North Am 1995,9:97-116.
4Sarosi GA.Amphotericin B.Still the gold standard for antifungal therapy.Postgrad Med 1990,88:151-66.
5Graybill JR.The future of antifungal therapy.Clin Infect Dis 1996,22(2 Suppl):Sl66-S178.
6Perfect JR Lindsay MH.Drew RH.Adverse drug reactions to systemic antifungals,Prevention and management Drug Saf 1992,7:323-63.
7Janoff AS.Boni LT.Popescu MC,et al.Unusual lipid structures selectively reduce the toxicity of amphotericin B.Proc Natl Acad Sci U S A 1988,85:6122-6.
8Janoff AS.Perkins WR,Saletan SL.Swenson CE.Amphotericin B lipid complex (ABLC 228).a molecular rationale for the atrenuation of ampholericin B related tosicities.J Liposonme Res 1993,3:451-71.
9Hiemenz JW.Lister LW.Anaissie EJ.et al.Emergency-use amphotericin B lipid complex(ABLCD in the treatment of patients with aspergillosis:historical-control comparison with amphotericin B.Blood 1995,86:A3383.
10Lister J.Amphotericin B lipid complex (Abelcer) in the treatment of invasive mycoses:the North American experience.Eur J Hacematol 1990,56:18-23.

世界医学杂志

1998年第11期

内容加载中请稍等...